NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that data for DANYELZA® (naxitamab-gqgk), omburtamab and nivatrotamab will be presented at the Company’s R&D event, which takes place virtually today at 12 p.m. Eastern Time. Key opinion leaders, including Shakeel Modak, M.D., MRCP, Memorial Sloan Kettering (“MSK”), Jaume Mora, M.D., Ph.D., SJD Barcelona Children's Hospital, and Brian H. Santich, Ph.D., MSK, will discuss the current treatment landscape and unmet medical needs for high-risk neuroblastoma, osteosarcoma and other solid tumors. Investors, analysts, members of the media and public may access the event via a live webcast.

Read more:
Y-mAbs Announces Pipeline Update

Original post:
BioSyent Launches Combogesic®, First-Ever Acetaminophen + Ibuprofen Combination Tablet in Canada Now Available

An Emerging Markets News Commentary An Emerging Markets News Commentary

Visit link:
Emerging Markets Report: Doctor’s Orders

Excerpt from:
AB Science will host a live webcast on December 17, 2020 on masitinib results in Alzheimer’s Disease

DURHAM, N.C., Dec. 16, 2020 (GLOBE NEWSWIRE) -- CoImmune, Inc. today announced that its CAR-CIK technology was featured at the annual American Society of Hematology (ASH) meeting with an interim update on the phase 1/2 dose escalation clinical trial in B-cell acute lymphoblastic leukemia (B-ALL). The trial is being conducted at Ospedale San Gerardo, Monza, Italy by principal investigator Andrea Biondi, M.D. and at Papa Giovanni XXIII, Bergamo, Italy by principal investigator Alessandro Rambaldi, M.D. The presentation on was on December 7th during the immunotherapy session and was given by Dr. Chiara Magnani of the Tettamanti Research Center, Monza, Italy.

See the original post here:
Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH

Read more here:
Tauriga Sciences Inc. Obtains its FEDLINKS Badge as a Verified Federal Government Vendor

Continue reading here:
Tauriga Sciences Inc. to Resume the Clinical Development of its Proposed “Anti-Nausea” Pharmaceutical Grade Version of Tauri-Gum

COPENHAGEN, Denmark, December 16, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised an option covering the majority of the second year of performance under the USD $200 million order for JYNNEOS® (Smallpox and Monkeypox Vaccine, Live, Non-replicating) awarded in April 2020.

Visit link:
Bavarian Nordic Secures Second Part of Smallpox Vaccine Order from the U.S. Government

WALTHAM, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. has submitted its response to the FDA’s Notice of Opportunity for a Hearing (“NOOH”) regarding the Agency’s proposal to withdraw approval for Makena—also referred to as 17-OHPC—the only FDA-approved treatment, along with five generic versions, to reduce preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.

Read more:
AMAG Pharmaceuticals Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw...

--Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications----Adelia brings a range of technologies related to novel therapeutics, delivery methods, and therapeutic regimens, along with six patent applications--

See the article here:
CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings

SAN DIEGO, Dec. 14, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company’s CEO John W. Huemoeller II will be presenting at the 13th Annual LD Micro Main Event investor conference on Monday, December 14, 2020, at 11:00 a.m. PST/2:00 p.m. EST.

Visit link:
AXIM® Biotechnologies to Present at the 13th Annual LD Micro Main Event Investor Conference on Monday, December 14

STRATHROY, Ontario, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V: EVE; OTCQX: EEVVF) is pleased to announce that it has successfully completed its non-brokered financing of unsecured convertible debentures in the principal amount of Cdn$550,000 (the “Debentures”) to certain individuals, including the Company’s Chief Executive Officer, Melinda Rombouts. The proceeds from the Debentures will be utilized for general working capital purposes.

Excerpt from:
Eve & Co Completes Issuance of $550,000 Convertible Debentures

REDWOOD CITY, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Dawn Svoronos as an independent member of Adverum’s Board of Directors. Ms. Svoronos has three decades of global biopharmaceutical industry experience, spanning the United States, Canada, Europe, and Asia, gained during her 25-year career at Merck & Co.

Link:
Adverum Biotechnologies Appoints Pharmaceutical Industry Veteran Dawn Svoronos to Board of Directors

See original here:
Tauriga Sciences Inc. Surpasses the 10,000 Follower(s) Threshold on its Instagram Page - @taurigum

Combined Company to Trade on NASDAQ Post-closing under Tickers: RVPH and RVPHW

Read more:
Reviva Pharmaceuticals, Inc. and Tenzing Acquisition Corp. Complete their Business Combination and Trade as Reviva Pharmaceuticals Holdings, Inc.

Industry leaders bolster engineering, technology and professional services for Aktana’s growing customer roster Industry leaders bolster engineering, technology and professional services for Aktana’s growing customer roster

Go here to see the original:
Aktana Hires Key Executives to Meet Escalating Demand for AI in Life Sciences

Provides an efficient mechanism for delivering CBD to help treat all forms of pain Provides an efficient mechanism for delivering CBD to help treat all forms of pain

Go here to read the rest:
Per Os Biosciences Expands Patent Portfolio for Chewing Gum Compositions Incorporating Cannabinoids

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive LifeSciencesInvestorForum.com Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive LifeSciencesInvestorForum.com

Read more:
Bionexus Gene Lab Corp to Webcast Live at Life Sciences Investor Forum December 17th

Company’s leading role in accelerating decentralized clinical trial adoption further reinforces its commitment to Patients-First approaches Company’s leading role in accelerating decentralized clinical trial adoption further reinforces its commitment to Patients-First approaches

Link:
Parexel Joins Decentralized Trials & Research Alliance (DTRA) to Enhance Patient Access, Increase Diversity and Accelerate Trial Timelines

Geneva, Switzerland, December 14, 2020 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for a proposed underwritten public offering of shares, including those to be settled in the form of American Depositary Shares (ADSs). Each ADS represents the right to receive six shares of Addex.  The terms of the offering have not been determined, and the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. The Company will be concurrently offering the shares in Europe (other than Switzerland) in a private placement to qualified investors, and in Switzerland through private placements.

Visit link:
Addex Announces Filing of Registration Statement for Proposed Public Offering of Securities